TRAX
First Tracks Biotherapeutics Inc. · NASDAQ
- Market cap
- $1.98B
First Tracks Biotherapeutics Inc. (TRAX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 16 wire items for TRAX, including 7 SEC filings, 4 insider trades and 2 press releases and news items. The most recent was published Nov 12, 2026.
TRAX rankings
News · 26 weeks59+114%
2026-05-242026-11-15
Mix3190d
- SEC Filings10(32%)
- Insider8(26%)
- Other6(19%)
- Analyst4(13%)
- 13D/G2(6%)
- Offering1(3%)
Activity · 52 weeks9940 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GSEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G/A - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 424B3 filed by First Tracks Biotherapeutics Inc.424B3 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- INSIDERChief Financial Officer Tamboli Ajim was granted 42,500 shares (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERPresident, CEO Faga Daniel was granted 136,000 shares (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERChief Business Officer Stone Benjamin was granted 42,500 shares (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- INSIDERChief Medical Officer Lizzul Paul F. was granted 42,500 shares (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- SECSEC Form 10-Q filed by First Tracks Biotherapeutics Inc.10-Q - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECFirst Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference, Boston Format – Fireside chat and one-on-one investor meetingsDate and Time – Tuesday, Nov. 10, 2026 at 11:30am ET Jefferies Global Healthcare Conference, London Format – Presentation and one-on-one investor meetingsDate and Time – Monday, Nov. 16, 2026 at 4:30pm GMT
- PRFirst Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateAnnounced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD)Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in CeD; top-line data anticipated in Q1 2027Anticipate initiating late-stage clinical trial for ANB033 in CeD in 2027Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-line data anticipated in Q3 2027Anticipate initiating Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027Completed private placement with $200 million in gross proceeds; pro
- SECSEC Form EFFECT filed by First Tracks Biotherapeutics Inc.EFFECT - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by First Tracks Biotherapeutics Inc.SCHEDULE 13G/A - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)
- SECSEC Form S-1 filed by First Tracks Biotherapeutics Inc.S-1 - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 8-K filed by First Tracks Biotherapeutics Inc.8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- SECSEC Form 8-K filed by First Tracks Biotherapeutics Inc.8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces $200 Million Private PlacementSAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, 202
- SECSEC Form 8-K filed by First Tracks Biotherapeutics Inc.8-K - First Tracks Biotherapeutics, Inc. (0002091349) (Filer)
- PRFirst Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac DiseaseANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009)LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001)Prevented an increase in symptoms throughout the entire gluten challenge, with lower CDSD score on ANB033 vs. placebo that was statistically significant from the first dayWell tolerated with no safety signals observed to dateConference call and webcast today, Monday, Oct. 12, 2026, at 8:30 a.m. ET to discu
- PRFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT. A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a
- ANALYSTCanaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price targetCanaccord Genuity initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $50.00
- ANALYSTEvercore ISI initiated coverage on First Tracks Biotherapeutics with a new price targetEvercore ISI initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $65.00
- INSIDERDirector Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
- ANALYSTGuggenheim initiated coverage on First Tracks Biotherapeutics with a new price targetGuggenheim initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $100.00
TRAX FAQ
6 questionsWhat is the latest news on TRAX?
In the last 30 days Quantisnow tracked 16 wire items for TRAX: 7 SEC filings, 4 insider trades, 2 press releases and news items and 2 13D/G filings. The most recent was published on November 12, 2026.Where does TRAX stock trade?
First Tracks Biotherapeutics Inc. (TRAX) is listed on NASDAQ.What sector and industry is TRAX in?
First Tracks Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TRAX?
First Tracks Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $50.00 price target on 2026-09-30. Recent price targets range from $30.00 to $100.00.What companies are similar to TRAX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare TRAX side-by-side with any of them on Quantisnow.How can I track TRAX on Quantisnow?
Quantisnow aggregates First Tracks Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAX to receive live email and push alerts on every new disclosure.